Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
Bektas
M
M
Bektas
H
H
Gören
D
D
Altan
M
M
Cetinkaya
H
H
D000998:Antiviral Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000175:diagnosis; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin